Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease

NCT00456859 | Completed Phase 4 DMC

• 1 other identifier: CAP-KD ver.3
• Study Type: interventional
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel group comparison clinical trial and will be conducted as a researcher-directed study to assess the efficacy of Kremezin in preventing the progression of CKD. We compare two groups of patients: those receiving conventional treatment alone and those receiving such treatment paired with Kremezin.

Conditions

Kidney Failure, Chronic

Keywords

chronic kidney disease; oral carbonaceous adsorbent; randomized clinical trial; composite endpoint

Outcome Measures

Primary Outcomes (5)

• The composite primary endpoint comprises the following events:

• Doubling of serum Creatinine

• Increase in serum Creatinine to 6.0 mg/dl or more

• Endstage renal disease (ESRD; defined as that requiring dialysis or renal transplantation)

• Death

Secondary Outcomes (4)

• Variation in urinary protein

• Changes in Creatinine Clearance

• Changes in health-related quality of life (HRQOL)

• Occurrence of adverse events

Interventions

Kremezin DRUG

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject is an outpatient.
• The subject is 20 years of age or older at the time of consent to participate in the study.
• The subject's serum creatinine value is 5.0 mg/dl or less at the time of case registration.
• The inverse serum creatinine value, calculated using measurements at four or more time points during an observation period that occurs within 48 weeks of case registration, is decreasing, on average, according to linear-regression analysis performed at the case registration center.
• The subject's blood pressure is well controlled before the initial serum creatinine measurement during the observation period.
• The subject has been treated with an ACEI and/or ARB before the initial serum creatinine measurement during the observation period.
• The subject has undergone low-protein diet therapy (\> 0.8 g/kg per day) before the initial serum creatinine measurement during the observation period.
• The subject has not changed the type or dose of medication for renal failure for 4 weeks prior to case registration.
• The subject has participated in thorough consultation and has been informed as to the purpose, description, expected adverse effects, and risks of this study according to the consent form, and has voluntarily signed the informed consent form.

You may not qualify if:

• The subject has a passage disorder of the gastrointestinal tract.
• The subject has been treated with Kremezin within the period from the initial measurement of the serum creatinine level prior to case registration to the time of study commencement.
• The subject has rapid progressive glomerular nephritis, hydronephrosis, occlusive urinary tract injury, drug-induced nephropathy, or transplanted kidney.
• The subject has complications such as severe hepatopathy, liver cirrhosis, severe infection, class III or above New York Heart Association (NYHA) congestive heart failure, severe arrhythmia, or unstable angina.
• The subject has had cardiac infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months.
• The subject presents with severe nephrotic syndrome (serum albumin \< 2 g/dl).
• The subject is currently pregnant, or plans to become pregnant during the study period.
• The subject abuses alcohol.
• The subject has a body weight less than 80% or more than 160% of the standard weight {\[height(m)\]\^2 x 22}.
• The subject has significant difficulty in controlling his/her blood sugar level within 3 months of case registration (hemoglobin \[Hb\]A1c \> 8.0% on one occasion).
• The subject has a progressive malignant tumor.
• The subject is not available for study visits at least once per 2 months to provide urine samples.
• The subject is inappropriate for participation in the study for other reasons, as determined by an investigator.

Sponsors & Collaborators

• Institute for Health Outcomes and Process Evaluation Reseach: lead

Study Sites (1)

iHope International

Tokyo, 102-0072, Japan

Location

Related Publications (2)

• Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol. 2005 Sep;9(3):219-27. doi: 10.1007/s10157-005-0358-7.

  PMID: 16189630 BACKGROUND

• Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009 Sep;54(3):459-67. doi: 10.1053/j.ajkd.2009.05.011. Epub 2009 Jul 17.

  PMID: 19615804 DERIVED

MeSH Terms

Conditions

Kidney Failure, Chronic; Renal Insufficiency, Chronic

Interventions

AST 120

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Yasushi Asano

  Jichi Medical University

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: April 4, 2007
• First Posted: April 5, 2007
• Study Start: April 1, 2004
• Study Completion: September 1, 2007
• Last Updated: October 18, 2007

Record last verified: 2007-10

Locations

JP (1)